The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trialsJonathan I. Silverberg, Jonathan Zalevsky, Carsten Schmitz et al.|Nature Communications|2024Cited by 37
Standardization of Lesion Classification and Assessment by Investigators in Clinical Trials for Hidradenitis SuppurativaAmit Garg, John R. Ingram, Andrew Strunk et al.|JAMA Dermatology|2025Cited by 4
729 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled, international, multicenter, study to evaluate the efficacy and safety of rezpegaldesleukin in adults with moderate-to-severe atopic dermatitisMelinda Gooderham, David Rosmarin, Charles Lynde et al.|British Journal of Dermatology|2024Cited by 2
REZPEGALDESLEUKIN, NOVEL TREG-INDUCING THERAPY, DEMONSTRATES EFFICACY IN ATOPIC DERMATITIS AND ASTHMA IN PHASE 2B TRIALJonathan Corren, David Rosmarin, P. Lio et al.|Annals of Allergy Asthma & Immunology|2025Cited by 1
724 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin in adults with severe to very-severe alopecia areataDavid Rosmarin, Charles Lynde, Neil S. Sadick et al.|British Journal of Dermatology|2024Cited by 0